[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558214":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":63,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":26,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":26,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fexofenadine hydrochloride","EXPERIMENTAL","Fexofenadine hydrochloride 60mg bid was added to the standard treatment 3 days after the completion of primary PCI and CMR examination for 6 months.",[13],"Drug: Fexofenadine Hydrochloride",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive a matched 60mg placebo tablet orally twice a day for 6 months, which was added to the standard treatment.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Fexofenadine Hydrochloride","Fexofenadine hydrochloride 60mg bid treatment for 6 months on the basis of standard treatment.",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo administration for 6 months on the basis of standard treatment.",[15],[31],{"name":32,"affiliation":33,"role":34},"Xinyang Hu, PhD","2nd Affiliated Hospital, School of Medicine, Zhejiang University, China","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Yinchuan Xu, PhD","CONTACT","86-13968126628","lsyrmxyc@126.com",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Feimu Zhang, MSt","86-18888915610","feimuzhang@zju.edu.cn",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"The 2nd Affiliated Hopital of Zhejiang University, School of Medicine","RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":55,"coordinates":56},"Point",[57,58],120.16142,30.29365,{"lat":58,"lon":57},[61],{"name":62,"role":38,"phone":39,"phoneExt":26,"email":40},"Prof. Yinchuan Xu",{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100558214","effect-and-safety-of-fexofenadine-hydrochloride-vs-placebo-in-patients-with-acute-myocardial-infaction-a-randomized-clinical-trial-100558214",false,"NCT06548204","Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial","FEND-AMI","Inclusion Criteria:\n\n* Ages above 18;\n* Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He\u002Fshe or his\u002Fher legal representative shall provide written informed consent before participating in the clinical trial.\n* Meet the diagnostic criteria for STEMI, the diagnostic criteria includes:\n\n  1. Clinical symptoms: ischemic chest pain lasting for over 30 minites;\n  2. Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);\n  3. ST segment elevation: new ST segment elevation in two or more adjacent leads on the ECG;\n* Emergency coronary angiography and revascularization should be performed;\n* Ultrasonic cardiogram indicates regional wall motion abnormality, and transthoracic echocardiography shows LVEF ≤ 50% within 72 hours after revascularization.\n\nExclusion Criteria:\n\n* Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;\n* Previously suffered from myocardial infarction or received coronary artery bypass grafting;\n* Patients with concomitant cardiomyopathy or valve disease;\n* History of severe renal failure, estimated glomerular filtration rate (eGFR) \\\u003C 30ml\u002Fmin;\n* History of severe liver dysfunction;\n* Concurrent severe infections, or liver\u002Fgallbladder obstruction, or history of malignant tumors;\n* Currently receiving immunosuppressive therapy;\n* Pregnant or potentially pregnant and breastfeeding women;\n* Contraindications for fexofenadine hydrochloride or cardiac magnetic resonance examinations;\n* Without obtaining written informed consent.\n* Patients with hemodynamic instability.","ALL","18 Years",{"count":75,"type":76},152,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.",[82],"ST-segment Elevation Myocardial Infarction (STEMI)","2026-08-05",{"date":85,"type":86},"2026-08-10","ACTUAL",{"date":88,"type":86},"2025-01-20",{"date":90,"type":76},"2027-12-30",{"name":5,"class":6},1]